Welcome to the Starpharma investor centre.Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
SPL7013 in VIRALEZE™ virucidal against Omicron (ASX Announcement)
Mar 1st, 2022
Starpharma today announced that SPL7013, the antiviral agent in VIRALEZE™ antiviral nasal spray, achieved the maximal possible reduction of virus infectivity (>95% within 1 minute of exposure and >99% within 5 minutes, achieving a maximal reduction of >99.5%) against the Omicron variant of SARS-CoV-2, in laboratory-based antiviral and virucidal assays. Testing of SPL7013 against Omicron was conducted in the laboratory of internationally recognised virologist, Professor Philippe Gallay, at The Scripps Research Institute in the US.
Read More
Dr Jeff Davies appointed as non-executive director (ASX Announcement)
Feb 24th, 2022
Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.
Read More
VIRALEZE™ sales and distribution in Saudi Arabia and GCC (ASX Announcement)
Feb 3rd, 2022
Starpharma today announced it has signed an exclusive sales and distribution agreement for VIRALEZE™ antiviral nasal spray in Saudi Arabia and eight other countries, including the GCC[1] countries (United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain), with Etqan & Nazahah LLC (E&N). E&N is an agent and distributor of medical and pharmaceutical products, headquartered in Saudi Arabia, that represents international healthcare companies, including Bayer, in the GCC region and other neighbouring countries.
Read More
Quarterly Cashflow and Activities Report (ASX Announcement)
Jan 28th, 2022
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2021.
Read MoreReports & Presentations
Click here for financial reports archive
Quarterly Cashflow and Activities Report (ASX Announcement)
Apr 29th, 2022
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.
Read More
Quarterly Cashflow and Activities Report (ASX Announcement)
Jan 28th, 2022
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2021.
Read More
AGM Chairman’s address and CEO’s presentation (ASX Announcement)
Nov 30th, 2021
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.
Read More
Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)
Nov 9th, 2021
Starpharma has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.
Read More
Quarterly Cashflow and Activities Report (ASX Announcement)
Oct 29th, 2021
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2021.
Read More
Starpharma annual report and full year financial results (ASX Announcement)
Aug 26th, 2021
Starpharma today released its annual report and financial results for the year ended 30 June 2021.
Read More
Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)
Jun 24th, 2021
Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.
Read More